KIT and breast carcinoma: In the context of breast cancer, genes within the conserved signatures, such as those that characterize the more purified luminal progenitor subset (for example, KIT, CYP24A1, ELF5), have the potential to provide novel prognostic markers or therapeutic targets in breast cancer.